Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Epidiolex is a prescription oral liquid containing cannabidiol at 100 mg per mL. It is approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients age 1 and older. Dosing is based on body weight and the seizure disorder being treated.
read more about epidiolex ...The precise anticonvulsant mechanism of cannabidiol in humans is unknown. Current labeling states that its seizure-reducing effects do not appear to result from interaction with cannabinoid receptors. Cannabidiol is metabolized mainly in the liver and has several clinically relevant drug interactions.
Epidiolex treats seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients age 1 and older. Liver transaminases and total bilirubin are checked before therapy starts. Dose adjustments are used in moderate or severe liver impairment.
For Lennox-Gastaut syndrome or Dravet syndrome, treatment starts at 2.5 mg per kg twice daily and rises after one week to 5 mg per kg twice daily. The dose can rise to 10 mg per kg twice daily. Tuberous sclerosis complex starts at the same dose and titrates to 12.5 mg per kg twice daily.
Serious concerns include liver injury, sleepiness and sedation, suicidal thoughts or behavior, hypersensitivity reactions, and increased seizure frequency or status epilepticus after abrupt withdrawal. Liver injury risk rises with higher Epidiolex doses and with valproate. Clobazam can also increase sedation and influence liver-related risk.
It treats seizures linked to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex from age 1.
Epidiolex contains cannabidiol at a concentration of 100 mg per mL.
Yes. ALT, AST, and total bilirubin are checked before treatment and monitored during therapy.
No. Gradual dose reduction is used to reduce the risk of increased seizures and status epilepticus.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/33346789/. Date Accessed September 29, 2026.
Cannabidiol: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a618051.html. Date Accessed September 29, 2026.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. https://pubmed.ncbi.nlm.nih.gov/29768152/. Date Accessed September 29, 2026.
EPIDIOLEX (Cannabidiol) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec. Date Accessed September 29, 2026.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. https://pubmed.ncbi.nlm.nih.gov/28538134/. Date Accessed September 29, 2026.